Abstract
The number of patients with diabetes mellitus in the Andijan region who were registered according to endocrinologists from 2000 to 2015 increased almost fourfold from 26,000 to more than 110,000 in 2016 (14). This also shows that the number of patients with various purulent-necrotic complications of diabetes mellitus also increases proportionally, in addition, there is an increase in patients with severe purulent-septic complications of these processes, with widespread, deep purulent-necrotic fasciitis [3]. Of patients in the department of surgical infection of the ASMI clinic, patients with purulent-necrotic complications of diabetes mellitus account for almost 78%, which indicates a significant increase in the number of these patients. This tendency continues and goes up every year. According to the WHO, by 2030 every 15 people will have diabetes, and by 2050 this figure will be equal to every 6 people.
Highlights
The clinical picture of purulent-necrotic complications in patients with diabetic foot syndrome is characterized by a peculiar course
In order to create a rational concentration of antibiotics in parts of the body affected by purulent-necrotic processes, as well as to restore local blood flow, in order to provide oxygen to regenerating cells, which are the basis for the regeneration of purulent-necrotic wounds, an intra-arterial method of introducing the proposed complex of drugs introduced through A .Femoralis of the affected side
Antibiotic therapy was used on the basis of the concept of rational antibiotic therapy, which indicates the use of at least two types of synergistic antibiotics in purulent-necrotic processes, one of which can be used for intraarterial administration
Summary
The clinical picture of purulent-necrotic complications in patients with diabetic foot syndrome is characterized by a peculiar course. This is due to ischemia of the affected area in varying degrees of severity, high bacterial contamination, with a tendency to spread the purulent process in the surrounding tissues and tendon sheaths and a significant decrease in the general and local reactivity of tissues [1, 3, 4, 8, 13,17,18,19], The USA Journals Volume 03 Issue 06-2021. The hormone dexamethasone inhibits the development of such processes [1], and midocalm, no-shpa increases the blood supply to the limb and lowers peripheral resistance [10,12,13,15]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American Journal of Medical Sciences and Pharmaceutical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
